Evidence map›Paper›PMID 40075680›Full record

ArticleCancers2025

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption.

Dongzheng Gai, Perry C Caviness, Oxana P Lazarenko, Jennifer F Chen, Christopher E Randolph, Zijun Zhang, Yan Cheng, Fumou Sun, Hongwei Xu, Michael L Blackburn and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dongzheng GaiMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Perry C CavinessArkansas Children's Nutrition Center, Little Rock, AR 72205, USA.
Oxana P LazarenkoArkansas Children's Nutrition Center, Little Rock, AR 72205, USA.
Jennifer F ChenUndergraduate Pre-Medical Program, University of Arkansas at Fayetteville, Fayetteville, AR 72701, USA.
Christopher E RandolphCenter for Translational Pediatric Research, Arkansas Children's Research Institute, Little Rock, AR 72202, USA.
Zijun ZhangMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Yan ChengMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-7877-9622
Fumou SunMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Hongwei XuMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Michael L BlackburnArkansas Children's Nutrition Center, Little Rock, AR 72205, USA.ORCID 0000-0002-4126-3750
Guido TricotMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
John D ShaughnessyMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jin-Ran ChenArkansas Children's Nutrition Center, Little Rock, AR 72205, USA.
Fenghuang ZhanMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-5417-2973

Funding

Prevention of MGUS Progression to MM by Modulating the Bone Marrow MicroenvironmentU54CA272691 · NCI · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Yong Li · 2023 to 2026
$6.1M
The role of oxidative stress in alcohol-induced osteopeniaR37AA018282 · NIAAA · LSU HEALTH SCIENCES CENTER · PI RONIS, MARTIN J J · 2016 to 2025
$4.7M
Towards a better understanding of the critical role and therapeutic potential of drug resistant genes in multiple myelomaR01CA236814 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI FENGHUANG ZHAN · 2020 to 2026
$2.5M
NEK2 Over-expression Causes Drug Resistance in MyelomaR01CA152105 · NCI · UNIVERSITY OF UTAH · PI ZHAN, FENGHUANG · 2010 to 2014
$1.5M
BLRD VA I01 BX006235National Institute of Health R37 AA18282NCI NIH HHS 1R01CA236814-01A1NCI NIH HHS R01 CA152105NCI NIH HHS R01 CA236814NCI NIH HHS U54 CA272691NCI NIH HHS U54CA272691-01NIAAA NIH HHS R37 AA018282
6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignancy of terminally differentiated B-cells that is localized primarily in the bone marrow (BM) but also can be present in peripheral blood and tissue/organs [...].

Indexed as

bone biologybone diseasehematologymultiple myelomaosteoclast/osteoblast biology

Identifiers

PMID40075680
PMCPMC11899016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.